Danaher DHR
$230.25 +$3.91 (+1.73%)
Market closed · Nov 8, 8:10 pm ET · Last extended-hours $230.25 0.00%
Open$222.96
Prev close$226.34
Day range$222.96 – $230.66
Volume4.06M
Market cap$161.99B
P/E (TTM)37.7
Dividend yield0.66%
Ownership & positioning
Who holds it, who is betting against it, and where the big money is moving
Institutional ownership82.9%-0.91 pts vs. prior quarter
Institutions holding2,549+40 vs. prior quarter
Insider trades (recent)34 buys / 7 sellsNet buying
Short interest1.16% of floatDays to cover 1.9 · as of 15 Oct 2026
Short-sale volume share11.8%5-day average of daily volume
Short-sale volume as % of daily volume
Large-order net flow, last 20 sessions
Net of large-order buying minus selling, in USD. Over this window: −$213.12M (3 inflow days, 17 outflow days).
Net flow by order size, last 20 sessions
Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.
The five largest holders on file together own 29.1% of shares outstanding.
Largest holders
By investor type
Reported short interest has fallen from 1.72% to 1.16% of float over the last 6 biweekly reports (31 Jul 2026 to 15 Oct 2026).
Recent institutional activity
| Holder | Type | Period | Share change | New stake |
|---|---|---|---|---|
| FMR | Mutual Fund | 2026/Q3 | +6,343,439 | 3.8% |
| BlackRock | Mutual Fund | 2026/Q3 | +3,444,011 | 7.8% |
| Capital Research | Mutual Fund | 2026/Q3 | +3,426,673 | 3.8% |
| Eagle Capital Management LLC | Mutual Fund | 2026/Q3 | +2,786,331 | 1.3% |
| Millennium Management LLC | Hedge Fund | 2026/Q3 | +1,970,805 | 0.3% |
| Wellington Management Group | Mutual Fund | 2026/Q3 | +1,542,310 | 2.3% |
| Arrowstreet Capital, Limited Partnership | Mutual Fund | 2026/Q3 | +1,523,429 | 0.7% |
| Castle Hook Partners LP | Hedge Fund | 2026/Q3 | +1,245,389 | 0.3% |
| Janus Henderson Group plc | Mutual Fund | 2026/Q3 | +1,155,744 | 1.1% |
| Glenview Capital Management, LLC | Hedge Fund | 2026/Q3 | +989,704 | 0.2% |
| The Goldman Sachs Group, Inc. | Public Company | 2026/Q3 | +850,401 | 0.3% |
| Southpoint Capital Advisors LP | Hedge Fund | 2026/Q3 | +800,000 | 0.2% |
| Royal London Asset Management Ltd. | Mutual Fund | 2026/Q3 | +681,996 | 0.1% |
| Strategic Advisers LLC | Mutual Fund | 2026/Q3 | +663,127 | 0.4% |
| Anomaly Capital Management, LP | Hedge Fund | 2026/Q3 | +602,649 | 0.2% |
Institutional buy/sell activity by reporting period, largest moves first.
Insider transactions
| Date | Insider | Title | Transaction | Shares | Price | Held after |
|---|---|---|---|---|---|---|
| 8 Oct 2026 | Steven Rales | Chairperson | Sale to Issuer | -500,000 | – | 42,240,800 |
| 8 Oct 2026 | Daniel Comas | Director | Initial Statement of Beneficial | +0 | – | 85,254 |
| 8 Oct 2026 | Mitchell Rales | Co-Founder | Sale to Issuer | -500,000 | – | 33,771,695 |
| 30 Sep 2026 | Shashanka Muppaneni | Chief Strategy Officer | Initial Statement of Beneficial | +0 | – | 53,718 |
| 30 Sep 2026 | Heathre Moler | Senior VP & CHRO | Initial Statement of Beneficial | +0 | – | 44,241 |
| 20 Aug 2026 | Rainer Blair | Senior Advisor | Open Market Disposition | -58,255 | $219.35 | 37,988 |
| 3 Aug 2026 | Steven Rales | Chairperson | Other Acquisition | +500,000 | – | 500,000 |
| 3 Aug 2026 | Steven Rales | Chairperson | Other Derivative Acquisition | +1,000,000 | $194.78 | 1,000,000 |
| 3 Aug 2026 | Mitchell Rales | Co-Founder | Other Acquisition | +500,000 | – | 500,000 |
| 3 Aug 2026 | Mitchell Rales | Co-Founder | Other Derivative Acquisition | +1,000,000 | $194.78 | 1,000,000 |
| 3 Aug 2026 | Gregory Milosevich | Executive Vice President of Life Sciences Business | Other Acquisition | +15,402 | – | 20,354 |
| 3 Aug 2026 | Jose-Carlos Gutierrez-Ramos | Senior VP & Chief Science Officer | Other Acquisition | +13,477 | – | 24,289 |
| 3 Aug 2026 | Matthew Gugino | Chief Financial Officer | Other Derivative Acquisition | +153,563 | $194.78 | 153,563 |
| 3 Aug 2026 | Jonathan Leiken | Chief Legal Officer | Other Derivative Acquisition | +92,138 | $194.78 | 92,138 |
| 3 Aug 2026 | Christopher Riley | Executive VP of Biotechnology Group & CEO of Cytiva | Other Acquisition | +41,072 | – | 57,316 |
| 3 Aug 2026 | Christopher Bouda | Vice President | Other Derivative Acquisition | +12,286 | $194.78 | 12,286 |
| 3 Aug 2026 | Julie Montgomery | Chief Executive Officer | Other Derivative Acquisition | +245,701 | $194.78 | 245,701 |
| 30 Jul 2026 | Alan Spoon | Independent Director | Other Derivative Acquisition | +229 | – | 31,043 |
| 30 Jul 2026 | Elias Zerhouni | Independent Director | Other Derivative Acquisition | +236 | – | 18,709 |
| 30 Jul 2026 | Raymond Stevens | Independent Director | Other Derivative Acquisition | +181 | – | 7,428 |
From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.
Short interest, by report
| Report date | Shares short | % of float | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 8,143,543 | 1.2% | 1.9 |
| 30 Sep 2026 | 8,969,401 | 1.3% | 1.8 |
| 15 Sep 2026 | 8,344,032 | 1.2% | 2.7 |
| 31 Aug 2026 | 9,639,180 | 1.4% | 2.8 |
| 14 Aug 2026 | 8,781,182 | 1.2% | 2.7 |
| 31 Jul 2026 | 12,074,192 | 1.7% | 1.4 |
No comments yet — be the first to weigh in on DHR.
Sign in to join the discussion.